WO2007118984A1 - Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques - Google Patents
Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques Download PDFInfo
- Publication number
- WO2007118984A1 WO2007118984A1 PCT/FR2007/000558 FR2007000558W WO2007118984A1 WO 2007118984 A1 WO2007118984 A1 WO 2007118984A1 FR 2007000558 W FR2007000558 W FR 2007000558W WO 2007118984 A1 WO2007118984 A1 WO 2007118984A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- roscovitine
- use according
- diseases
- disease
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the field of treatment and prevention of neurological diseases particularly associated with neurological lesions related in particular to the phenomenon of excitotoxicity. It particularly relates to a new therapeutic application of S-roscovitine, whose chemical name is 6 (benzylamino) 2 (S) [[1 (hydroxymethyl) propyl] amino] -9-zisopropylpurine).
- Excitotoxicity is an accumulation of excitatory amino acids that excessively activate glutamate receptors leading to neuronal death (Olney JW and Ishimaru MJ, 1999;
- Excitotoxic cell death This is death and diseases of the nervous system. Humana Press Inc .: 197-219).
- Excitatory amino acids represent a group of structural analogues of glutamate comprising many members including aspartate, kainate and some of its derivatives, known to represent powerful neuronal exciters. Glutamate is unquestionably the most well characterized excitatory amino acid. The effect of excitatory amino acids is transmitted by metabotropic and ionotropic glutamate NMDA-type
- Excitotoxicity thus plays a major role in the development of neurological lesions associated with many neurological diseases including acute and chronic. (Choi, 1988, Trends Neurosci, 11, pp. 465-459, Coyle and Puttfarcken, 1993, Science, 262, pp. 689-695, Lipton and Rosenberg, 1994, New Engl J Med, vol 330, pgs. 613-622).
- neuroprotective compounds prevent and / or treat neurological lesions in particular. related to the phenomenon of excitotoxicity.
- the inventors have discovered that the S isomer of roscovitine solves all or part of the problems mentioned above and has a better neuroprotective efficacy than that of the R isomer.
- the inventors have now identified and characterized a particular compound, (S) -roscovitine for preventing and / or effectively treating neurological lesions particularly related to the phenomenon of excitotoxicity.
- (S) -roscovitine inhibits more weakly different cyclin-dependent protein kinases (cdk) involved in the cell division cycle or apoptosis than (R) -roscovitine.
- cdk cyclin-dependent protein kinases
- the inhibitory activity of (S) -roscovitine on cdk-5, cdk-1 / cyclin B and cdc2 / cyclin B protein kinases is lower than that of (R) -roscovitine (De Azevedo et al. al., Eur J.
- the subject of the invention is the use of (S) -roscovitine or 6- (benzylamino) -2 (S) - [[1- (hydroxymethyl) propyl] amino] -9-isopropylpurine or at least one of its pharmaceutically acceptable salts for the manufacture of a medicament for the prevention and / or treatment of neurological diseases.
- (S) -roscovitine is understood to mean the compound of the following formula:
- the enantiomeric excess can be defined by the formula ((S) -roscovitine - (R) -roscovitine / (S) -roscovitine + (R) -roscovitine) x 100.
- (S) -roscovitine can be obtained according to techniques well known to those skilled in the art, for example by a three-step synthesis from 2,6-dichloropurine as described by Havlicek et al. (J. Med Chem, 1997, 40, 408) and by Wang et al. (Tetrahefron: Asymmetry, 2001, 12, 2891).
- (S) -roscovitine is also available from Alexis Corporation as ALX-350-293-M001.
- pharmaceutically acceptable salts means salts suitable for pharmaceutical use.
- pharmaceutically acceptable salts mention may be made of benzene sulphonate, hydrobromide, hydrochloride, citrate, ethanesulphonate, fumarate, gluconate, iodate, isethionate, maleate and methanesulphonate.
- Neurological disease is generally understood to mean diseases characterized by “neurological lesions”.
- Neurological lesions means a structural alteration of the nervous system in its anatomical and physiological characteristics.
- the lesion can be microscopic or macroscopic.
- the lesion may be of traumatic origin or caused by a disease, particularly acute or chronic neurological diseases. These neurological lesions can affect different cell types, neurons, astrocytes, oligodendrocytes, microglia and progenitors of these cells.
- the neurological lesions are related to the excitotoxicity phenomenon.
- the prevention and / or treatment of neurological lesions is related to the neuroprotective activity of (S) -roscovitine.
- Neural cells are the cells of the nervous system and especially of the brain. These neural cells can in particular be chosen from neurons, astrocytes and oligodendrocytes. Neuroprotection is particularly interesting in the case of neurological diseases including acute or chronic. Indeed, these diseases can be associated with degeneration of neural cells leading to their death. This can therefore make possible the use of compounds for preventing and / or delaying the death of these neural cells, or at least a portion of these neural cells, healthy and / or diseased.
- neural cells die immediately, or almost immediately, defining a so-called “necrotic heart” area.
- penumbra adjacent to the necrotic heart, in which the cells can be progressively affected before ending in cell death.
- neuroprotective therapeutic agents can prevent the evolution of at least a portion of these cells to neural death.
- the neurological diseases are chronic neurological diseases.
- chronic neurological diseases is understood to mean neurological diseases, the symptoms of which may initially be weak, and which may progressively change and worsen, for example over a period of several years.
- Chronic neurological diseases include: neurodegenerative diseases (Adams and
- - dementia including Alzheimer's disease, vascular dementia, Lewy body disease, frontotemporal dementia, cortico-basal degeneration, Huntington's chorea and other neurodegenerative diseases, including amyotrophic lateral sclerosis, Creutzfeld-Jakob disease (Choi, 1988, Coyle and Puttfarcken,
- demyelinating diseases including multiple sclerosis, disseminated acute allergic encephalitis, Devic's disease (neuromyelopathy) and genetic diseases with myelin involvement including Pelizaeus-Merzbacher disease.
- the neurological diseases are acute neurological diseases, in particular ischemic stroke.
- Acute neurological diseases means neurological diseases, the symptoms and clinical signs of which may be initially very marked and which may stabilize rapidly, for example after a few days.
- Acute neurological diseases include:
- cerebral hemorrhage intraparenchymal haemorrhage and meningeal haemorrhage. After subarachnoid hemorrhage, ischemia may occur in connection with vasospasm. S-Roscovitine may prevent or reduce cerebral ischemia following meningeal hemorrhage.
- certain cerebral haemorrhages may be related to the use of a thrombolytic agent, in particular the tissue activator of plasminogen (t-PA).
- a thrombolytic agent in particular the tissue activator of plasminogen (t-PA).
- t-PA tissue activator of plasminogen
- S-roscovitine may therefore be useful in combination with a thrombolytic agent to reduce the risk of cerebral haemorrhage by protecting the blood-brain barrier.
- S-roscovitine may act as an anti-aptoptic agent against cerebral endothelial cells. Cerebral endothelial cells are one of the major components of the blood-brain barrier.
- the medicament according to the invention may also comprise at least one anti-neurodegenerative agent, in particular an agent intended to fight and / or prevent diseases. chronic and / or acute neurologic and more specifically, ischemic stroke.
- anti-neurodegenerative agent a compound for combating and / or preventing degeneration of the nervous system.
- anti-neurodegenerative agents include inhibitors of acetylcholinesterase such as donepezil, selegiline, rivastigmine, galantamine, antiglutamatergics such as memantine and riluzole.
- S-Roscovitine may be used in combination with an anti-cholinesterase drug (donepezil, rivastigmine, galantamine) or antiglutamatergic drug (memantine) in Alzheimer's disease or other dementias, such as vascular dementia, bodily disease of Lewy, frontotemporal dementia, cortico-basal degeneration, Huntington's chorea, parkinsonian dementia ... roscovitine could be used in combination with riluzole in amyotrophic lateral sclerosis.
- (S) -roscovitine and the anti-neurodegenerative agent can be administered simultaneously, separately or in a time-spread manner.
- (S) -roscovitine and the anti-neurodegenerative agent may be present in the medicament according to the invention in a molar ratio ranging from 10/1 to 1/10.
- the medicament according to the invention may further comprise at least one thrombolytic agent.
- thrombolytic agent a substance capable of lysing blood clots, such as plasminogen activator (t-PA), streptokinase, urokinase and desmoteplase.
- t-PA plasminogen activator
- streptokinase streptokinase
- urokinase urokinase
- desmoteplase plasminogen activator
- (S) -roscovitine and the thrombolytic agent can be administered simultaneously, separately or in a time-spread manner.
- (S) -roscovitine and the thrombolytic agent may be present in the medicament according to the invention in a molar ratio ranging from 100/1 to 1/100.
- Thrombolytic agents may have side effects, they may for example cause brain hemorrhages.
- the use of (S) -roscovitine in combination with at least one thrombolytic agent, in particular t-PA, may make it possible to reduce some of these side effects, and in particular the risk of cerebral hemorrhage.
- the medicament according to the invention may further comprise at least one antiplatelet agent.
- antiplatelet agent By way of example of “antiplatelet agent”, mention may be made of acetylsalicylic acid, ticlopidine hydrochloride, clopidogrel, dipyridamole, abciximab, flurbiprofen.
- S-roscovitine may be used in combination with a platelet aggregating agent in ischemic stroke.
- (S) -roscovitine and antiplatelet agent may be administered simultaneously, separately or over time.
- (S) -roscovitine and antiplatelet agent may be present in the medicament according to the invention in a molar ratio ranging from 10/1 to 1/10.
- Said medicaments according to the invention are administrable by different routes.
- administration routes that can be used for the medicaments according to the invention, mention may be made of the oral, rectal, cutaneous, pulmonary, nasal, sublingual, parenteral, especially intradermal, subcutaneous, intramuscular, and intravenous routes. intra-arterial, intra-spinal, intra-articular, intrapeloral, intraperitoneal.
- the preferred administration routes for the medicaments according to the invention are the intravenous, intramuscular, sublingual or cutaneous route, most preferably the intravenous route and the intramuscular route and, preferably, among all the intravenous route.
- the preferred route of administration for the medicaments according to the invention is the oral route.
- the medicaments according to the invention can be administered in one or more times or in continuous release, in particular by continuous infusion.
- the medicaments according to the invention may be in various forms, in particular in a form selected from the group consisting of tablets, capsules, lozenges, syrups, suspensions, solutions, powders, granules, emulsions , microspheres and injectable solutions, preferably tablets, injectable solutions, sublingual sprays and skin patches.
- Formulations suitable for parenteral administration, pharmaceutically acceptable vehicles suitable for this route of administration and the corresponding formulation and administration techniques may be carried out according to methods well known to those skilled in the art, in particular those described in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa., 20th Edition, 2000).
- 6- (benzyl-amino) -2 (1 S ') - [[1- (hydroxymethyl) propyl] amino] -9-isopropylpurine) or at least one pharmaceutically acceptable salt thereof is present in the medicament in an amount ranging from 50 mg to 5 g per unit dose, in particular from 100 mg to 2 g.
- the medicament according to the invention may be administered in one or more doses per day, preferably in 1 to 4 doses per day.
- the (S) -roscovitine may be administered in an amount ranging from 1 to 200 mg / kg per day.
- the medicament comprises an amount of 6- (benzyl-amino) -2 (S) - [[1-
- said medicament further comprises a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier means any material that is suitable for use in a pharmaceutical product.
- a pharmaceutically acceptable carrier examples include lactose and starch. optionally modified, cellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, mannitol, sorbitol, xylitol, dextrose, calcium sulphate, calcium phosphate, calcium lactate, dextrates, inositol, calcium carbonate, glycine, bentonite, polyvinylpyrrolidone, and mixtures thereof.
- the medicament according to the invention may comprise a content of pharmaceutically acceptable carrier ranging from 5% to 99% by weight, in particular from 10% to 90% by weight, and in particular from 20% to 75% by weight relative to the total weight of the composition. .
- FIG. 1 illustrates in the form of a histogram the neuroprotective effect of (S) -roscovitine in an in vitro model of excitotoxicity: a mixed neural culture (astrocytes, neurons, oligodendrocytes) of exposed hippocampus cells. to kainate. (** p ⁇ 0.05; * p ⁇ 0.01 with a Student t-test).
- Figure 2 illustrates in graphical form the neuroprotection (CN50) concentration of (S) -roscovitine in a mixed neural culture of hippocampus cells exposed to kainate.
- FIG. 3 illustrates in the form of a histogram the effect of (S) -roscovitine at different incubation times on a mixed neural culture of cells of the hippocampus exposed to kainate. (** p ⁇ 0.05; * p ⁇ 0.01 with a Student t-test).
- Figure 4 illustrates the neuroprotective effect of (S) -roscovitine in a complex in vitro model of excitotoxicity: a rat rat hippocampal organotypic slice culture.
- A Observation of cell death in the rat hippocampus CA3 region after propidium iodide labeling and incubation with either DMSO and H 2 O (control), either kainate or kainate and S) -Roscovitine.
- Figure 5 illustrates the characterization of the "necrotic heart” and "penumbra” regions in mouse brains in an in vivo model of permanent fetal ischemia.
- A Photograph of coronal sections of an adult mouse brain stained with 2,3,5 triphenyl tetrazolium chloride (TTC), 3 hours after MCAo. Three regions coronales can be identified and delimited according to their intensity of coloring: "the necrotic heart”, “the penumbra” and healthy tissue.
- TTC triphenyl tetrazolium chloride
- Three regions coronales can be identified and delimited according to their intensity of coloring: “the necrotic heart”, “the penumbra” and healthy tissue.
- B Measurement using ImageJ software of relative staining intensities of "necrotic heart", “penumbral area” and healthy tissue stained by 2,3,5 TTC, 3 hours after MCAo. (* p ⁇ 0.01 with a Student t-test).
- FIG. 6 illustrates in histogram form the neuroprotective effect of (S) -roscovitine in an in vivo mouse model of permanent focal ischemia.
- (S) -roscovitine was administered intracerebroventricularly (IVC) (A) or systemically (PI) (B). Cell death was assessed by measuring the relative intensities of staining in the necrotic heart, the penumbra area. (* p ⁇ 0.01 with a Student t-test).
- Figure 7 illustrates the comparison of the neuroprotection index (IN) of (S) -roscovitine and (R) -roscovitine in an in vitro model of excitotoxicity: a mixed neural culture of exposed hippocampus cells to kainate.
- Figure 8 illustrates kainate-induced selective neuronal death from mixed cultures of seahorses:
- a neuronal excitotoxicity model was developed using 10-day mixed hippocampal cultures subjected to kainate treatment. Fluorescence microscopy of cultures in control condition (left) or treated with 200 ⁇ M kainate (right) and immunolabeled with class III anti-beta-tubulin antibody (top) or cell death marker propidium iodide (PI, bottom). Note the decrease in cell density characterized by beta-tubulin and the increase of propidium iodide-labeled cells in kainate-treated cultures compared to control cultures.
- Kainate a glutamatergic agonist
- kainate induces programmed cell death compared to NMDA agonists that induce necrotic death (Portera-Cailliau, 1997). This programmed death is also visible in acute and chronic neurological diseases.
- the importance and relevance of glutamate has recently been underlined by the fact that commercially available anti-glutamatergic drugs are currently used in humans in Alzheimer's disease (Memantine, Reisberg 2003, N. Eng J. Med, 348). 1333-1341) and amyotrophic lateral sclerosis (Riluzole).
- Cultured cells were incubated for 5 hours with kainate and / or test compounds prior to observation of neuronal death. Controls were incubated only with DMSO and H 2 O vehicles.
- Neuronal death was assessed by observation by phase contrast microscopy and by the use of propidium iodide (PI) which is a marker of cell death.
- PI propidium iodide
- Propidium iodide is a red marker, which specifically binds to the nucleic acids of dead cells.
- Representative field neurons were enumerated. At least 5 fields per condition (the total number of neurons being about 150) were examined from 3 independent cultures.
- the percentage of neuronal death was expressed as the ratio of the number of neurons labeled with propidium iodide to the total number of neurons visualized by phase contrast microscopy.
- MNR % neuronal death (KA + test compounds) -% neuronal death (control) /% neuronal death (KA) -% neuronal death (control) and
- the concentration of test compounds required to obtain a neuroprotection index (IN) of 50% was designated CN50: neuroprotection concentration.
- the neuroprotection index (IN) as defined above was respectively 18.5%, 49.2%, 72.1%, 78.4% and 84.7% for doses of S-roscovitine of 0.05 ⁇ M, 0.1 ⁇ M, 0.5 ⁇ M, 1 ⁇ M, and 5 ⁇ M.
- the therapeutic window of the neuroprotective effect of (S) -roscovitine was determined by measuring its ability to protect the neurons when the compound was added to the culture medium either at the same time or at the same time. different times before (1 hour, RT) or after (1 hour, 2 hours or 3 hours, T + 1, T + 2, T + 3) addition of kainate. Different concentrations of (S) -roscovitine were studied (0.5 ⁇ M, 1 ⁇ M and 5 ⁇ M).
- MNR neuronal death
- the neuroprotection index (IN) as defined above was respectively 76.6%, 110.4%, 114.4% at TI, 72.1%, 78.4%, 84.7% at TO, 35.1%, 69.3%, 80.5% at T + 1, 33.6%, 55.2%, 85.3% at T + 2, and 29.0%, 28.3%, 34.7% at T + 3 for doses of (S) -roscovitine of 0.5 ⁇ M, 1 ⁇ M, and 5 ⁇ M.
- the neuroprotective effect of (S) -roscovitine is observed when the compound is added to cultures up to 2 hours after the toxic agent.
- the effect of (S) -roscovitine is dose-dependent.
- (S) -roscovitine has a preventive effect - on the neuronal death induced by kainate.
- Organotypic cultures were performed from hippocampi of 2-day old rats (P2) using the method of Stoppini et al. (1991, J. Neurosci Methods, 37, pages 173-182). Rats are sacrificed by decapitation. The brain is dissected in dissection medium (PBS IX, glucose 5.85 g / l) at 4 ° C. Cross sections of a thickness of 400 ⁇ m are made using a tissue chopper (Mc Ilwain) . Once separated, the slices are cultured on inserts with porous membranes (0.4 ⁇ m) and transparent (30 mm in diameter), in culture medium (MEM IX, 20% horse serum, insulin 1 mg / l). The entire culture medium is replaced every two days.
- PBS IX dissection medium
- Mc Ilwain tissue chopper
- the cultures are maintained at 37 ° C. in an incubator where the atmosphere is enriched with CO 2 (5%) and moist.
- the serum-containing culture medium is replaced by fresh medium devoid of serum and in the presence of propidium iodide (IP, 7.5 ⁇ M).
- IP propidium iodide
- the medium is replaced by fresh medium devoid of serum containing IP and kainate (5 ⁇ M) and / or (S) -roscovitine (20 ⁇ M).
- the controls were incubated only with the vehicles (DMSO and H20).
- the cultures are fixed after 24 hours with a solution of paraformaldehyde 4%.
- Cell death is quantified using propidium iodide labeling with ImageJ (NIH) software. The intensity of the PI is measured in the CA3 region for each treatment condition.
- the neuroprotective effect is examined by determining relative neuronal death as a parameter (MNR) as defined in the previous paragraph (1.1.1.).
- This model consists of unilateral occlusion by electrocoagulation of the middle cerebral artery in adult animals (MCAo, modified method of Tamura et al., 1981, Cereb Blood Flow Metab, vol 1, pages 53-60). In mice, this model causes an almost exclusive involvement of the temporoparietal cortex of the ipsi-lateral hemisphere. These lesions are visible for 3 hours after MCA and their size extends over time to reach a maximum at 24 hours (Guegan et al., 1998, Exp Neurol, 154, pages 371-380).
- (S) -roscovitine was administered in two modes: intracerebroventricular and systemic.
- ICV intracerebroventricular route
- (S) _roscovitine was administered at the concentration of 25 mg / kg in 0.05M HCl solution by performing 2 intraperitoneal injections 15 minutes before and 1 hour after the occlusion of the MCA. Control animals received only vehicles (1% DMSO for ICV and 0.05M HCl for PI).
- the volume of brain lesions was estimated by staining with 2,3,5 triphenyl tetrazolium chloride (TTC). This staining is based on the proper functioning of mitochondrial enzymes. The intensity of staining reflects the number of functional mitochondria. This coloration thus makes it possible to differentiate injured regions from healthy regions.
- the animals were sacrificed by cervical dislocation 3 hours after the occlusion of MCA. The brains were dissected and sectioned into 1 mm thick coronal slices. The slices were then stained with a 1% TTC solution for 10 minutes and analyzed using the NIH ImageJ software.
- (S) -roscovitine at a concentration of 0.5 ⁇ M makes it possible to obtain an MNR of 27.9% whereas a concentration of 0.5 ⁇ M of (R) -roscovitine makes it possible to obtain a MNR of 62% . Under these conditions, (S) -roscovitine prevents the death of 2 times more neurons than R-roscovitine.
- the concentration of neuroprotection (CN50) of (R) -roscovitine is 0.65 ⁇ M while it is 0.19 ⁇ M for (S) -roscovitine. It takes more than three times more (R) -roscovitine than (S) -roscovitine to prevent the death of the same number of neurons.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07731236T ATE479438T1 (de) | 2006-03-30 | 2007-03-30 | Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen |
US12/225,834 US8318707B2 (en) | 2006-03-30 | 2007-03-30 | Administration of (S)-roscovitine for protection against and/or treatment of neurological diseases |
CA2647694A CA2647694C (fr) | 2006-03-30 | 2007-03-30 | Utilisation de la (s)-roscovitine pour la prevention et/ou le traitement de maladies neurologiques |
EP07731236A EP1998778B1 (fr) | 2006-03-30 | 2007-03-30 | Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques |
SI200730433T SI1998778T1 (sl) | 2006-03-30 | 2007-03-30 | Uporaba (s)-roskovitina za prepreäśevanje in/ali zdravljenje nevroloĺ kihn motenj |
BRPI0709446-9A BRPI0709446A2 (pt) | 2006-03-30 | 2007-03-30 | uso do 6-(benzilamino)-2 (s)- [[1-(idroximetil)propil]amino]-9-isopropilpurina) |
JP2009502153A JP5405295B2 (ja) | 2006-03-30 | 2007-03-30 | 神経疾患の予防または治療のうち少なくともいずれかを行うための(s)−ロスコビチンを含む医薬品 |
DE602007008855T DE602007008855D1 (de) | 2006-03-30 | 2007-03-30 | Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen |
PL07731236T PL1998778T3 (pl) | 2006-03-30 | 2007-03-30 | Zastosowanie (s)-roskowityny w profilaktyce i/lub leczeniu chorób neurologicznych |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0602773A FR2899107B1 (fr) | 2006-03-30 | 2006-03-30 | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
FR0602773 | 2006-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007118984A1 true WO2007118984A1 (fr) | 2007-10-25 |
Family
ID=37054697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/000558 WO2007118984A1 (fr) | 2006-03-30 | 2007-03-30 | Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques |
Country Status (13)
Country | Link |
---|---|
US (1) | US8318707B2 (fr) |
EP (1) | EP1998778B1 (fr) |
JP (1) | JP5405295B2 (fr) |
CN (1) | CN101454009A (fr) |
AT (1) | ATE479438T1 (fr) |
BR (1) | BRPI0709446A2 (fr) |
CA (1) | CA2647694C (fr) |
DE (1) | DE602007008855D1 (fr) |
ES (1) | ES2352520T3 (fr) |
FR (1) | FR2899107B1 (fr) |
PL (1) | PL1998778T3 (fr) |
SI (1) | SI1998778T1 (fr) |
WO (1) | WO2007118984A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104386A2 (fr) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Méthode de traitement d'amyloïdoses |
WO2010034863A1 (fr) * | 2008-09-23 | 2010-04-01 | Consejo Superior De Investigaciones Científicas (Csic) | Utilisation d'inhibiteurs de kinases pour la préparation de compositions pharmaceutiques pour le traitement de la maladie de parkinson, compositions pharmaceutiques et méthode de diagnostic de la maladie de parkinson |
JP2011504474A (ja) * | 2007-11-22 | 2011-02-10 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー氏病を治療するためのMnkインヒビターの使用 |
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
EP2710120A1 (fr) * | 2011-05-17 | 2014-03-26 | University of Central Florida Research Foundation, Inc. | Neurones électriquement actifs stables provenant de tissus adultes |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
WO2023114462A1 (fr) * | 2021-12-17 | 2023-06-22 | Belhaven BioPharma Inc. | Contre-mesures médicales comprenant des formulations de poudre sèche et procédés associés |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020842A1 (fr) * | 1995-12-01 | 1997-06-12 | Centre National De La Recherche Scientifique (C.N.R.S.) | Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques |
EP0911634A1 (fr) * | 1997-10-24 | 1999-04-28 | Het Nederlands Kanker Instituut | Regulateurs de CDK-2 et leurs utilisations pharamaceutiques |
WO2001070231A2 (fr) * | 2000-03-22 | 2001-09-27 | Centre National De La Recherche Scientifique -Cnrs- | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aiguës |
US20030069259A1 (en) * | 2000-10-31 | 2003-04-10 | David Borcherding | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
EP1348707A1 (fr) * | 2002-03-28 | 2003-10-01 | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) | Pyrazolo[4,3-d]pyrimidines, procédé pour leur préparation et application thérapeutique |
WO2004026246A2 (fr) * | 2002-09-17 | 2004-04-01 | New York University | Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire |
WO2006021803A2 (fr) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Methode de traitement et compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU735127B2 (en) * | 1997-08-07 | 2001-06-28 | Regents Of The University Of California, The | Purine inhibitor of protein kinases, G proteins and polymerases |
ATE318818T1 (de) * | 1998-06-16 | 2006-03-15 | Us Gov Health & Human Serv | Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen |
ATE253918T1 (de) * | 1999-12-08 | 2003-11-15 | Centre Nat Rech Scient | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel |
FR2804959B1 (fr) * | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
US20040254094A1 (en) * | 2000-10-11 | 2004-12-16 | The Trustees Of University Of Pennsylvania And Board Of Regents | Suppression of cyclin kinase activity for prevention and treatment of infections |
AU2002305260A1 (en) * | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
EP1388541A1 (fr) * | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines utilisées comme inhibiteurs de kinases |
AU2003302747A1 (en) * | 2002-12-17 | 2004-07-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness |
FR2876583B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
-
2006
- 2006-03-30 FR FR0602773A patent/FR2899107B1/fr not_active Expired - Fee Related
-
2007
- 2007-03-30 US US12/225,834 patent/US8318707B2/en active Active
- 2007-03-30 SI SI200730433T patent/SI1998778T1/sl unknown
- 2007-03-30 EP EP07731236A patent/EP1998778B1/fr not_active Not-in-force
- 2007-03-30 BR BRPI0709446-9A patent/BRPI0709446A2/pt not_active Application Discontinuation
- 2007-03-30 JP JP2009502153A patent/JP5405295B2/ja active Active
- 2007-03-30 WO PCT/FR2007/000558 patent/WO2007118984A1/fr active Application Filing
- 2007-03-30 CA CA2647694A patent/CA2647694C/fr not_active Expired - Fee Related
- 2007-03-30 PL PL07731236T patent/PL1998778T3/pl unknown
- 2007-03-30 CN CNA2007800186403A patent/CN101454009A/zh active Pending
- 2007-03-30 DE DE602007008855T patent/DE602007008855D1/de active Active
- 2007-03-30 AT AT07731236T patent/ATE479438T1/de not_active IP Right Cessation
- 2007-03-30 ES ES07731236T patent/ES2352520T3/es active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020842A1 (fr) * | 1995-12-01 | 1997-06-12 | Centre National De La Recherche Scientifique (C.N.R.S.) | Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques |
EP0911634A1 (fr) * | 1997-10-24 | 1999-04-28 | Het Nederlands Kanker Instituut | Regulateurs de CDK-2 et leurs utilisations pharamaceutiques |
WO2001070231A2 (fr) * | 2000-03-22 | 2001-09-27 | Centre National De La Recherche Scientifique -Cnrs- | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aiguës |
US20030069259A1 (en) * | 2000-10-31 | 2003-04-10 | David Borcherding | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
EP1348707A1 (fr) * | 2002-03-28 | 2003-10-01 | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) | Pyrazolo[4,3-d]pyrimidines, procédé pour leur préparation et application thérapeutique |
WO2004026246A2 (fr) * | 2002-09-17 | 2004-04-01 | New York University | Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire |
WO2006021803A2 (fr) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Methode de traitement et compositions |
Non-Patent Citations (6)
Title |
---|
ADAMS; VICTOR: "les maladies neurodégénératives", 1985, MCGRAW-HILL BOOK COMPANY |
BACH ET AL., THE JOURNAL OF BIOCHEMICAL CHEMISTRY, vol. 280, no. 35, pages 31208 - 31219 |
BACH STEPHANE ET AL: "Roscovitine targets, protein kinases and pyridoxal kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 35, September 2005 (2005-09-01), pages 31208 - 31219, XP002402137, ISSN: 0021-9258 * |
BEART P M ET AL: "Roles for cyclin-dependent and mitogen-activated protein kinases in kainate receptor-mediated apoptosis", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, & 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 702.3, XP008069586, ISSN: 0190-5295 * |
DE AZEVEDO ET AL., EUR. J. BIOCHEM., vol. 243, 1997, pages 518 - 526 |
MAPELLI MARINA ET AL: "Mechanism of CDK5/p25 binding by CDK inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 3, 10 February 2005 (2005-02-10), pages 671 - 679, XP002402136, ISSN: 0022-2623 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
WO2008104386A3 (fr) * | 2007-02-27 | 2009-02-12 | Abbott Gmbh & Co Kg | Méthode de traitement d'amyloïdoses |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
WO2008104386A2 (fr) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Méthode de traitement d'amyloïdoses |
JP2011504474A (ja) * | 2007-11-22 | 2011-02-10 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー氏病を治療するためのMnkインヒビターの使用 |
WO2010034863A1 (fr) * | 2008-09-23 | 2010-04-01 | Consejo Superior De Investigaciones Científicas (Csic) | Utilisation d'inhibiteurs de kinases pour la préparation de compositions pharmaceutiques pour le traitement de la maladie de parkinson, compositions pharmaceutiques et méthode de diagnostic de la maladie de parkinson |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
EP2710120A1 (fr) * | 2011-05-17 | 2014-03-26 | University of Central Florida Research Foundation, Inc. | Neurones électriquement actifs stables provenant de tissus adultes |
EP2710120A4 (fr) * | 2011-05-17 | 2015-05-20 | Univ Central Florida Res Found | Neurones électriquement actifs stables provenant de tissus adultes |
Also Published As
Publication number | Publication date |
---|---|
EP1998778A1 (fr) | 2008-12-10 |
CN101454009A (zh) | 2009-06-10 |
JP5405295B2 (ja) | 2014-02-05 |
CA2647694C (fr) | 2014-12-09 |
DE602007008855D1 (de) | 2010-10-14 |
EP1998778B1 (fr) | 2010-09-01 |
BRPI0709446A2 (pt) | 2011-07-12 |
FR2899107A1 (fr) | 2007-10-05 |
US20100008927A1 (en) | 2010-01-14 |
ATE479438T1 (de) | 2010-09-15 |
SI1998778T1 (sl) | 2011-01-31 |
US8318707B2 (en) | 2012-11-27 |
JP2009531399A (ja) | 2009-09-03 |
CA2647694A1 (fr) | 2007-10-25 |
ES2352520T3 (es) | 2011-02-21 |
FR2899107B1 (fr) | 2008-06-13 |
PL1998778T3 (pl) | 2011-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1998778B1 (fr) | Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques | |
CA2514948C (fr) | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament | |
WO2013120040A1 (fr) | Inhibition d'une voie ciblée pour améliorer la structure, le fonctionnement et l'activité musculaires dans la dystrophie musculaire | |
EP1635823A1 (fr) | Antagonistes rage utilises contre l'amylose et les maladies associees | |
JPH10513455A (ja) | 緑内障治療用のデプレニル化合物 | |
EP2305225A1 (fr) | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament | |
US20190381007A1 (en) | (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | |
FR2555050A1 (fr) | Compositions pharmaceutiques et procede de preparation de compositions de phosphatidylserine, utilisables au traitement de desordres du systeme nerveux central sans exercer d'effets sur la coagulation du sang | |
AU2010251044A1 (en) | Use of quinazoline derivatives for neurodegenerative diseases | |
Westmark et al. | Rescue of Fmr1KO phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056 | |
EP2037736A1 (fr) | Méthodes de traitement de maladies kystiques rénales | |
US6451837B1 (en) | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors | |
FR2823116A1 (fr) | Procede de preparation d'une extrait de feuilles de ginkgo biloba hautement enrichi en principes actifs | |
US20210128596A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
KR102428383B1 (ko) | 중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물 | |
EP4035669A1 (fr) | Préparation de médicament pour traiter la maladie d'alzheimer | |
EP1638559B1 (fr) | Utilisation de pyrazolopyridines pour le traitement de deficits cognitifs | |
JP2018515507A (ja) | アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法 | |
CA2716764A1 (fr) | Nouvelle utilisation de n-acetyl-taurinate de zinc | |
Buznikov et al. | Amyloid precursor protein 96–110 and β-amyloid 1–42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids | |
KR102374047B1 (ko) | N,N′-디아세틸-p-페닐렌디아민 화합물을 유효성분으로 포함하는 알츠하이머병 예방, 개선 또는 치료용 조성물 | |
JP2005504768A (ja) | アポトーシスに関連した疾患を治療するための方法および組成物 | |
WO2023175010A1 (fr) | Utilisation du bazedoxifene pour augmenter la survie musculaire | |
CA2403714A1 (fr) | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neuralesaigues | |
JP2023081768A (ja) | 脂肪肝治療剤、医薬組成物、治療方法、及びスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780018640.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07731236 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2647694 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009502153 Country of ref document: JP Ref document number: 2007731236 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12225834 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0709446 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080930 |